High-dose Dexamethasone Inhibits BAFF Expression in Patients with Immune Thrombocytopenia

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2009 Jun 6

PMID 19499314

Citations 9

Authors

Xiao-Juan Zhu

Yan Shi

Jian-Zhi Sun

Ning-Ning Shan

Jun Peng

Cheng-Shan Guo

Ping Qin

Ming Hou

Affiliations

Soon will be listed here.

Abstract

Introduction: B-cell activating factor belonging to the TNF family (BAFF) is elevated in several autoimmune diseases including immune thrombocytopenia (ITP). High-dose dexamethasone (HD-DXM) has shown its clinical efficacy in ITP patients.

Materials And Methods: The plasma BAFF concentration and BAFF mRNA were measured in ITP patients before and after oral administration of 40 mg/day DXM for four consecutive days by enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR. Moreover, we evaluated the effects of DXM on BAFF expression and proliferation of lymphocytes by ELISA, real-time quantitative PCR and cell proliferation respectively in in vitro experiment.

Results: Both plasma BAFF concentration and BAFF mRNA were significantly increased in active ITP patients at pretherapy when compared with controls (P < 0.001). After 4-day treatment with HD-DXM, the BAFF and BAFF mRNA were decreased, and lower than that for controls. In in vitro assays, we found DXM-inhibited BAFF, IFN-gamma expression, and the proliferation of lymphocytes in a dose-dependent manner.

Conclusion: These results suggest that BAFF expression is increased in ITP patients with active disease, and DXM is an effective inhibitor of BAFF production. As immunosuppressant, DXM may play its role in ITP treatment partly through regulating BAFF expression.

Citing Articles

B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis.

Satoh T, Takiguchi H, Uojima H, Kubo M, Tanaka C, Yokoyama F Ann Hematol. 2022; 101(11):2433-2444.

PMID: 36098792 DOI: 10.1007/s00277-022-04973-x.

Neutrophils contribute to elevated BAFF levels to modulate adaptive immunity in patients with primary immune thrombocytopenia by CD62P and PSGL1 interaction.

Xu P, Shao X, Ou Y, Zhan Y, Ji L, Zhuang X Clin Transl Immunology. 2022; 11(7):e1399.

PMID: 35782911 PMC: 9237625. DOI: 10.1002/cti2.1399.

Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia.

Liu X, Hou M Open Med (Wars). 2017; 11(1):97-100.

PMID: 28352775 PMC: 5329806. DOI: 10.1515/med-2016-0019.

The effects of Jieduquyuzishen prescription-treated rat serum on the BAFF/BAFF-R signal pathway.

Wu D, Xu L, Wen C, Xie G, Ji J, Pan J PLoS One. 2015; 10(2):e0118462.

PMID: 25689512 PMC: 4331425. DOI: 10.1371/journal.pone.0118462.

Genome-wide gene expression profiling reveals unsuspected molecular alterations in pemphigus foliaceus.

Malheiros D, Panepucci R, Roselino A, Araujo A, Zago M, Petzl-Erler M Immunology. 2014; 143(3):381-95.

PMID: 24813052 PMC: 4212952. DOI: 10.1111/imm.12315.

References

Kalled S, Ambrose C, Hsu Y . The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun. 2004; 8:206-42. DOI: 10.1159/000082105. View

Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H . Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol. 2006; 155(2):330-6. DOI: 10.1111/j.1365-2133.2006.07305.x. View

Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer J, Holler N . BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999; 189(11):1747-56. PMC: 2193079. DOI: 10.1084/jem.189.11.1747. View

Zhou Z, Chen Z, Li H, Chen X, Xu J, Gu D . BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity. 2008; 42(2):112-9. DOI: 10.1080/08916930802397848. View

Moore P, Belvedere O, Orr A, Pieri K, LaFleur D, Feng P . BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999; 285(5425):260-3. DOI: 10.1126/science.285.5425.260. View

Stohl W, Metyas S, Tan S, Cheema G, Oamar B, Xu D . B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003; 48(12):3475-86. DOI: 10.1002/art.11354. View

Ling Y, Cao X, Yu Z, Ruan C . Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007; 79(4):310-6. DOI: 10.1111/j.1600-0609.2007.00917.x. View

Thien M, Phan T, Gardam S, Amesbury M, Basten A, Mackay F . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20(6):785-98. DOI: 10.1016/j.immuni.2004.05.010. View

Nardelli B, Belvedere O, Roschke V, Moore P, Olsen H, Migone T . Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001; 97(1):198-204. DOI: 10.1182/blood.v97.1.198. View

10.

Pfaffl M, Horgan G, Dempfle L . Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30(9):e36. PMC: 113859. DOI: 10.1093/nar/30.9.e36. View

11.

Seyler T, Park Y, Takemura S, Bram R, Kurtin P, Goronzy J . BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005; 115(11):3083-92. PMC: 1257539. DOI: 10.1172/JCI25265. View

12.

Kuwana M, Kaburaki J, Ikeda Y . Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998; 102(7):1393-402. PMC: 508987. DOI: 10.1172/JCI4238. View

13.

Andersen J . Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994; 330(22):1560-4. DOI: 10.1056/NEJM199406023302203. View

14.

Batten M, Groom J, Cachero T, Qian F, Schneider P, Tschopp J . BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000; 192(10):1453-66. PMC: 2193190. DOI: 10.1084/jem.192.10.1453. View

15.

Szodoray P, Jonsson R . The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol. 2005; 62(5):421-8. DOI: 10.1111/j.1365-3083.2005.01688.x. View

16.

Rolink A, Tschopp J, Schneider P, Melchers F . BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol. 2002; 32(7):2004-10. DOI: 10.1002/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5. View

17.

Do R, Hatada E, Lee H, Tourigny M, Hilbert D, Chen-Kiang S . Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000; 192(7):953-64. PMC: 2193312. DOI: 10.1084/jem.192.7.953. View

18.

Berchtold P, Wenger M . Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood. 1993; 81(5):1246-50. View

19.

Olsson B, Andersson P, Jacobsson S, Carlsson L, Wadenvik H . Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost. 2005; 93(1):139-44. DOI: 10.1160/TH04-06-0385. View

20.

Cheng Y, Wong R, Soo Y, Chui C, Lau F, Chan N . Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003; 349(9):831-6. DOI: 10.1056/NEJMoa030254. View